DDOG
Datadog, Inc.
DDOG's fundamentals are strong and it looks cheap: trading at 256x earnings, below its usual 379x. Analysts expect strong earnings growth, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
DDOG Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
DDOG's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
DDOG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 62x | $184 | — |
| Cheap | 251x | $181 | -2.1% |
| Current | 256x | $184 | — |
| Fair | 379x | $273 | +48% |
| Expensive | 621x | $447 | +142% |
Historical ranges are pointers, not guarantees.
DDOG's PE is in its cheap range at 256x. If earnings grow as analysts expect, today's price would be 62x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
DDOG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Stable | |
| Broad | |
| Low |
DDOG has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
DDOG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.99 | +315% |
| Q3 2026 | $0.72 | +125% |
| Q2 2026 | $0.50 | +39% |
| Q1 2026 | $0.39 | -17% |
| Q4 2025 | $0.31 | -40% |
| Q3 2025 | $0.32 | -42% |
| Q2 2025 | $0.36 | -23% |
| Q1 2025 | $0.47 | +38% |
| Q4 2024 | $0.52 | +271% |
DDOG has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
DDOG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +35% |
| Q2 2026 | $1.1B | +36% |
| Q1 2026 | $1B | +32% |
| Q4 2025 | $953.2M | +29% |
| Q3 2025 | $885.7M | +28% |
| Q2 2025 | $826.8M | +28% |
| Q1 2025 | $761.6M | +25% |
| Q4 2024 | $737.7M | +25% |
DDOG's revenue has grown year over year every quarter since late 2020: $1.2B last quarter, up 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.2% | +6.9 points |
| Q2 2026 | 0.5% | +4.8 points |
| Q1 2026 | 0.7% | +2.4 points |
| Q4 2025 | 1% | -0.3 points |
| Q3 2025 | -0.7% | -3.6 points |
| Q2 2025 | -4.3% | -6.3 points |
| Q1 2025 | -1.6% | -3.6 points |
| Q4 2024 | 1.3% | -3.4 points |
DDOG has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over DDOG on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
DDOG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $279.1M | +19% |
| Q2 2026 | $306M | +65% |
| Q1 2026 | $323.3M | +23% |
| Q4 2025 | $318.2M | +24% |
| Q3 2025 | $234.7M | +6.5% |
| Q2 2025 | $184.9M | +16% |
| Q1 2025 | $262.8M | +33% |
| Q4 2024 | $257.5M | +23% |
DDOG has the edge over HIMS on cash flow, with more consistent year-over-year improvement.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
DDOG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +4M shares |
| 1 year | +3.6% | +13M shares |
| 3 years | +6.7% | +23.7M shares |
| 5 years | +21% | +64.8M shares |
| Available history | +14% | +47.2M shares |
DDOG has 375M diluted shares, up 3.6% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over DDOG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
DDOG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.6x | Very low |
| Q2 2026 | 7.0x | High |
| Q1 2026 | 18.2x | High |
| Q4 2025 | 123.2x | High |
| Q3 2025 | 94.8x | High |
| Q2 2025 | 16.5x | High |
| Q1 2025 | 6.9x | High |
| Q4 2024 | 3.6x | Elevated |
DDOG's net debt is less than a year of its operating earnings (EBITDA), down from more than 20 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
DDOG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.5 | Neutral |
| Stochastic | 16.7 | Oversold |
DDOG's weekly RSI is 43 (neutral) and its Stochastic is 17 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
DDOG PE vs Technology Sector
| Metric | DDOG | Sector median | Relative |
|---|---|---|---|
| PE | 256x | 28x | 820% above |
| PE % | 19 | 35 | 16 pts below |
DDOG is trading at 256x earnings, a 820% premium to the Technology sector's median of 28x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
DDOG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $244.3 | 24% below |
| 20 week MA | $243.6 | 24% below |
| 50 week MA | $189.3 | 2.6% below |
| 100 week MA | $161.1 | 14% above |
| 200 week MA | $134.5 | 37% above |
DDOG has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
DDOG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.1 | $106.3 | +194% |
| 2021 | $106.3 | $180.4 | +70% |
| 2022 | $180.4 | $72.4 | -60% |
| 2023 | $72.4 | $121.4 | +68% |
| 2024 | $121.4 | $146.0 | +20% |
| 2025 | $146.0 | $138.3 | -5.3% |
| 2026 YTD | $138.3 | $184.5 | +33% |
DDOG has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.